Contribution of Complement, Microangiopathy and Inflammation in Idiopathic Inflammatory Myopathies.

Publisher: IOS Press Country of Publication: Netherlands NLM ID: 101649948 Publication Model: Print Cited Medium: Internet ISSN: 2214-3602 (Electronic) NLM ISO Abbreviation: J Neuromuscul Dis Subsets: MEDLINE

Original Publication: Amsterdam : IOS Press

Myositis*/diagnosis ; Muscular Diseases*/pathology; Humans ; Capillaries/pathology ; Endothelial Cells/pathology ; Muscle, Skeletal/pathology ; Inflammation/pathology ; Atrophy/pathology

Purpose of Review: Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group characterized by muscle weakness and skin symptoms and are categorized into six subtypes: dermatomyositis (DM), polymyositis (PM), anti-synthetase syndrome (ASS), immune-mediated myopathy (IMNM), inclusion body myopathy (IBM), and overlap myositis. Myositis-specific autoantibodies were detected for the diagnosis and classification of IIM. This review highlights the pathogenic contributions of the complement system, microangiopathy, and inflammation in IIM.
Recent Findings: Deposition of complement around capillaries and/or the sarcolemma was observed in muscle biopsy specimens from patients with DM, ASS, and IMNM, suggesting the pathomechanism of complement-dependent muscle and endothelial cell injury. A recent study using human muscle microvascular endothelial cells showed that Jo-1 antibodies from ASS induce complement-dependent cellular cytotoxicity in vitro. Based on both clinical and pathological observations, antibody- and complement-mediated microangiopathy may contribute to the development of DM and anti-Jo-1 ASS. Juvenile DM is characterized by the loss of capillaries, perivascular inflammation, and small-vessel angiopathies, which may be related to microinfarction and perifascicular atrophy. Several serum biomarkers that reflect the IFN1 signature and microangiopathy are elevated in patients with DM. The pathological observation of myxovirus resistance protein A (MxA), which suggests a type 1 interferon (IFN1) signature in DM, supports the diagnosis and further understanding of the pathomechanism of IIM. A recent report showed that an increase in triggering receptor expressed on myeloid cells (TREM-1) around perimysial blood vessels and muscles in patients with IIM plays a role in triggering inflammation and promoting the migration of inflammatory cells by secreting proinflammatory cytokines, such as tumor necrosis factor α.
Summary: The deposition of complement in muscles and capillaries is a characteristic feature of DM, ASS, and IMNM. Microangiopathy plays a pathogenic role in DM, possibly resulting in perifascicular atrophy. Further understanding of the detailed pathomechanism regarding complement, microangiopathy, and inflammation may lead to novel therapeutic approaches for IIM.

Nat Rev Immunol. 2003 Jun;3(6):445-53. (PMID: 12776204)
Muscle Nerve. 2015 May;51(5):638-56. (PMID: 25641317)
N Engl J Med. 1986 Feb 6;314(6):329-34. (PMID: 3945256)
Neurology. 2014 Jul 29;83(5):426-33. (PMID: 24975859)
RMD Open. 2019 Feb 26;5(1):e000811. (PMID: 30886734)
Neurology. 2017 Jan 31;88(5):493-500. (PMID: 28039312)
J Microbiol Immunol Infect. 2016 Apr;49(2):264-70. (PMID: 25070283)
Brain Pathol. 2021 May;31(3):e12955. (PMID: 34043262)
J Immunol. 1989 Jun 15;142(12):4289-94. (PMID: 2656863)
Rheumatology (Oxford). 2016 Mar;55(3):470-9. (PMID: 26424834)
Brain Pathol. 2023 Jul;33(4):e13155. (PMID: 36882048)
Clin Exp Immunol. 1987 Apr;68(1):117-29. (PMID: 3308207)
Brain. 2018 Jun 1;141(6):1609-1621. (PMID: 29741608)
J Rheumatol. 1995 Feb;22(2):320-5. (PMID: 7738956)
J Neuroimmunol. 1996 Dec;71(1-2):227-9. (PMID: 8982124)
Front Neurol. 2022 Oct 18;13:952699. (PMID: 36330424)
Arthritis Rheum. 2012 Nov;64(11):3809-17. (PMID: 22740338)
J Rheumatol. 1994 Apr;21(4):739-43. (PMID: 8035403)
Ann Rheum Dis. 2019 Jan;78(1):131-139. (PMID: 30309969)
Arthritis Res Ther. 2014 Feb 03;16(1):R39. (PMID: 24484965)
Neurol Neuroimmunol Neuroinflamm. 2023 May 5;10(4):. (PMID: 37147138)
Neuropathol Appl Neurobiol. 2019 Jun;45(4):410-420. (PMID: 29770465)
Brain. 2016 Jul;139(Pt 7):1891-903. (PMID: 27190020)
J Rheumatol. 2016 Jan;43(1):161-8. (PMID: 26628598)
Arthritis Rheum. 1987 May;30(5):572-6. (PMID: 3109444)
J Immunol. 2000 May 15;164(10):4991-5. (PMID: 10799849)
Arthritis Rheumatol. 2020 Jan;72(1):179-191. (PMID: 31403245)
Pharmacol Ther. 2017 Sep;177:81-95. (PMID: 28245991)
J Cell Physiol. 2017 Dec;232(12):3286-3295. (PMID: 28063233)
J Neuroimmunol. 1999 Aug 3;98(2):130-5. (PMID: 10430046)
Rheumatol Immunol Res. 2022 Apr 20;3(1):1-10. (PMID: 36467022)
Ann Rheum Dis. 2009 Jun;68(6):836-43. (PMID: 18628284)
Arthritis Rheum. 2011 Feb;63(2):479-87. (PMID: 21280002)
J Pathol. 2014 Jul;233(3):258-68. (PMID: 24604766)
J Neurol Sci. 1996 Dec;144(1-2):171-5. (PMID: 8994120)
Curr Opin Rheumatol. 2011 Nov;23(6):595-604. (PMID: 21934500)
Arthritis Rheum. 2011 Jul;63(7):1961-71. (PMID: 21400483)
Best Pract Res Clin Rheumatol. 2009 Oct;23(5):665-78. (PMID: 19853831)
Neurology. 2016 Jul 19;87(3):299-308. (PMID: 27343066)
Arthritis Rheum. 2010 Oct;62(10):3088-92. (PMID: 20583106)
Arch Neurol. 1991 Jan;48(1):26-30. (PMID: 1986724)
Neurology. 2015 Mar 31;84(13):1346-54. (PMID: 25746564)
J Rheumatol. 2013 Mar;40(3):294-302. (PMID: 23322463)
Ann Rheum Dis. 2015 Jan;74(1):315-7. (PMID: 25269830)
Pediatr Rheumatol Online J. 2017 May 17;15(1):42. (PMID: 28514969)
Int J Mol Sci. 2017 May 18;18(5):. (PMID: 28524083)
Autoimmun Rev. 2019 Jul;18(7):658-664. (PMID: 31059843)
Arthritis Rheum. 2005 Oct;52(10):3175-80. (PMID: 16200621)
J Intern Med. 2016 Jul;280(1):4-7. (PMID: 27320358)
Front Neurol. 2023 Apr 25;14:1146015. (PMID: 37181575)
N Engl J Med. 2001 Apr 12;344(15):1140-4. (PMID: 11297706)
Brain. 2015 Sep;138(Pt 9):2485-92. (PMID: 26198592)
Ann Rheum Dis. 2017 Dec;76(12):1955-1964. (PMID: 29079590)
Immunol Med. 2023 Mar;46(1):9-14. (PMID: 36282924)
Ann Rheum Dis. 2021 Sep;80(9):1201-1208. (PMID: 33811031)
Arthritis Rheumatol. 2017 Dec;69(12):2271-2282. (PMID: 29106061)
Neurology. 2019 Sep 17;93(12):e1193-e1204. (PMID: 31434690)
Nature. 2001 Apr 26;410(6832):1103-7. (PMID: 11323674)
Curr Opin Rheumatol. 1997 Nov;9(6):527-35. (PMID: 9375282)
Front Neurol. 2019 Jun 04;10:554. (PMID: 31214105)
N Engl J Med. 1972 Feb 17;286(7):333-8. (PMID: 4550387)
N Engl J Med. 2001 Apr 5;344(14):1058-66. (PMID: 11287977)
J Rheumatol. 2002 Jun;29(6):1301-7. (PMID: 12064850)
Neurology. 2021 Jan 19;96(3):e448-e459. (PMID: 33277422)
Pediatr Int. 2001 Feb;43(1):109-11. (PMID: 11208016)
Lancet. 2003 Sep 20;362(9388):971-82. (PMID: 14511932)
J Autoimmun. 2007 Sep-Nov;29(2-3):174-86. (PMID: 17826948)
J Neuropathol Exp Neurol. 2021 Sep 27;80(9):812-820. (PMID: 34363679)
Neuromuscul Disord. 2004 May;14(5):337-45. (PMID: 15099594)
Acta Neuropathol Commun. 2014 Oct 23;2:154. (PMID: 25339355)
Arthritis Rheum. 2012 Dec;64(12):4078-86. (PMID: 22886447)
Ann Neurol. 2005 May;57(5):664-78. (PMID: 15852401)
Curr Opin Neurol. 2022 Oct 1;35(5):611-621. (PMID: 35942671)
Rheumatology (Oxford). 2020 Jan 1;59(1):224-232. (PMID: 31257434)
Eur J Cell Biol. 2012 Feb;91(2):139-49. (PMID: 22176919)
Int Immunol. 2015 Jul;27(7):327-32. (PMID: 25577193)
Ann Neurol. 1995 Nov;38(5):705-13. (PMID: 7486861)
Semin Arthritis Rheum. 2017 Apr;46(5):642-649. (PMID: 28088340)
Neuromuscul Disord. 2020 Jan;30(1):70-92. (PMID: 31791867)
PLoS One. 2014 Mar 19;9(3):e92171. (PMID: 24647150)
Arthritis Rheumatol. 2018 Jan;70(1):134-145. (PMID: 28941175)
Acta Neuropathol Commun. 2020 Aug 5;8(1):125. (PMID: 32758284)
Arthritis Rheum. 1994 Dec;37(12):1744-51. (PMID: 7986220)
Nat Immunol. 2006 Dec;7(12):1266-73. (PMID: 17110943)
Ann Transl Med. 2017 Jan;5(1):22. (PMID: 28164107)
Brain. 2016 Sep;139(Pt 9):e50. (PMID: 27267378)
Ann Neurol. 1990 Apr;27(4):343-56. (PMID: 2353792)
Ann Rheum Dis. 2005 Oct;64(10):1485-9. (PMID: 15829578)
J Neurol Sci. 1989 Dec;94(1-3):181-92. (PMID: 2614466)
Curr Opin Rheumatol. 2019 Nov;31(6):634-642. (PMID: 31464706)
N Engl J Med. 1991 Nov 21;325(21):1487-98. (PMID: 1658649)
N Engl J Med. 2015 Apr 30;372(18):1734-47. (PMID: 25923553)
Expert Rev Clin Immunol. 2022 Apr;18(4):413-423. (PMID: 35323101)
N Engl J Med. 1993 Dec 30;329(27):1993-2000. (PMID: 8247075)
Curr Opin Neurol. 2020 Oct;33(5):590-603. (PMID: 32852298)
JAMA Neurol. 2018 Dec 1;75(12):1528-1537. (PMID: 30208379)
J Bras Pneumol. 2011 Jan-Feb;37(1):100-9. (PMID: 21390438)
J Dermatol. 1993 Jan;20(1):30-4. (PMID: 8482749)
Neurology. 2022 Feb 15;98(7):e739-e749. (PMID: 34873015)
J Rheumatol. 2004 Mar;31(3):605-9. (PMID: 14994413)
Cells. 2019 Sep 21;8(10):. (PMID: 31546668)
Arthritis Rheumatol. 2014 Aug;66(8):2281-9. (PMID: 24756983)
Biomedicines. 2022 Aug 20;10(8):. (PMID: 36009583)
Front Immunol. 2018 Dec 18;9:2951. (PMID: 30619311)
J Autoimmun. 2023 May;137:102979. (PMID: 36535812)
J Clin Invest. 1994 Nov;94(5):1729-35. (PMID: 7962520)
Clin Immunol. 2006 Sep;120(3):319-25. (PMID: 16859997)
Chest. 2010 Dec;138(6):1464-74. (PMID: 21138882)
Front Immunol. 2018 Jun 22;9:1372. (PMID: 29988398)
Rheumatology (Oxford). 2018 Apr 1;57(4):671-676. (PMID: 29361142)

Date Created: 20231225 Date Completed: 20240109 Latest Revision: 20240117

20240117

PMC10789353

10.3233/JND-230168

38143369